The N.1 Institute for Health (N.1) is an internationally-recognised clinical stage research institute focused on N-of-1 medicine, where clinical trials are designed specifically for each patient that is recruited into one of our ongoing clinical studies. We currently have over 10 prospective clinical trials cleared/ongoing. N.1 is divided into 3 thrusts:
- N.1/Onco,
- N.1/Neuro, and
- N.1/Thrive.
All 3 thrusts specialize in the use of interventional artificial intelligence (AI) to optimise personalised combination therapy for solid and hematologic cancer patients (N.1/Onco), digital therapeutics to optimise personalised learning and prevent cognitive decline (N.1/Neuro), and training regimens to optimise human physical performance as part of our health and human potential portfolio (N.1/Thrive). We are comprised of a pre-eminent and multidisciplinary team with expertise in engineering, clinical trial innovation, behavioural sciences, strategy, and policy, among other domains.